AssetMark Inc’s Takeda Pharmaceutical TAK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $5.26M | Sell |
289,107
-25,580
| -8% | -$453K | 0.01% | 731 |
|
|
2026
Q2 | $5.04M | Buy |
314,687
+87,071
| +38% | +$1.44M | 0.01% | 727 |
|
|
2026
Q1 | $4.22M | Buy |
227,616
+71,496
| +46% | +$1.25M | 0.01% | 710 |
|
|
2025
Q4 | $2.43M | Buy |
156,120
+33,902
| +28% | +$485K | 0.01% | 811 |
|
|
2025
Q3 | $1.79M | Buy |
122,218
+26,498
| +28% | +$394K | ﹤0.01% | 843 |
|
|
2025
Q2 | $1.48M | Buy |
95,720
+9,181
| +11% | +$136K | ﹤0.01% | 839 |
|
|
2025
Q1 | $1.29M | Buy |
86,539
+372
| +0.4% | +$5.21K | ﹤0.01% | 820 |
|
|
2024
Q4 | $1.14M | Buy |
86,167
+5,185
| +6% | +$71.2K | ﹤0.01% | 823 |
|
|
2024
Q3 | $1.15M | Buy |
80,982
+4,500
| +6% | +$63.8K | ﹤0.01% | 764 |
|
|
2024
Q2 | $990K | Buy |
76,482
+890
| +1% | +$11.8K | ﹤0.01% | 769 |
|
|
2024
Q1 | $1.05M | Buy |
75,592
+3,864
| +5% | +$56.2K | ﹤0.01% | 721 |
|
|
2023
Q4 | $1.02M | Buy |
71,728
+193
| +0.3% | +$2.74K | ﹤0.01% | 669 |
|
|
2023
Q3 | $1.11M | Buy |
71,535
+1
| +0% | +$15 | ﹤0.01% | 598 |
|
|
2023
Q2 | $1.12M | Buy |
71,534
+4,946
| +7% | +$81K | ﹤0.01% | 590 |
|
|
2023
Q1 | $1.1M | Buy |
66,588
+51,648
| +346% | +$823K | ﹤0.01% | 587 |
|
|
2022
Q4 | $233K | Buy |
14,940
+1,090
| +8% | +$15.2K | ﹤0.01% | 798 |
|
|
2022
Q3 | $180K | Buy |
13,850
+988
| +8% | +$13.7K | ﹤0.01% | 776 |
|
|
2022
Q2 | $181K | Sell |
12,862
-960
| -7% | -$13.7K | ﹤0.01% | 753 |
|
|
2022
Q1 | $198K | Buy |
13,822
+1,152
| +9% | +$16.9K | ﹤0.01% | 731 |
|
|
2021
Q4 | $173K | Buy |
12,670
+667
| +6% | +$9.36K | ﹤0.01% | 728 |
|
|
2021
Q3 | $197K | Buy |
+12,003
| New | +$202K | ﹤0.01% | 570 |
|
|
2021
Q1 | – | Sell |
-62,049
| Closed | -$1.13M | – | 1523 |
|
|
2020
Q4 | $1.13M | Buy |
62,049
+24,680
| +66% | +$433K | 0.01% | 343 |
|
|
2020
Q3 | $667K | Buy |
37,369
+9,134
| +32% | +$166K | ﹤0.01% | 375 |
|
|
2020
Q2 | $506K | Buy |
28,235
+8,843
| +46% | +$159K | ﹤0.01% | 384 |
|
|
2020
Q1 | $294K | Sell |
19,392
-70,986
| -79% | -$1.29M | ﹤0.01% | 431 |
|
|
2019
Q4 | $1.78M | Buy |
90,378
+43,104
| +91% | +$825K | 0.01% | 317 |
|
|
2019
Q3 | $813K | Buy |
47,274
+39,829
| +535% | +$689K | 0.01% | 331 |
|
|
2019
Q2 | $132K | Buy |
7,445
+6,075
| +443% | +$111K | ﹤0.01% | 549 |
|
|
2019
Q1 | $28K | Buy |
+1,370
| New | +$27.6K | ﹤0.01% | 815 |
|
Other funds holding TAK
AssetMark Inc's TAK Position: Q3 2026 in Review
AssetMark Inc reduced its Takeda Pharmaceutical (TAK) stake by 8.1% in Q3 2026, selling an estimated $453K and leaving 289,107 shares worth $5.26M. The position accounts for 0.01% of the portfolio, ranked #731.
AssetMark Inc first reported a position in TAK in Q1 2019 and has held it in 29 quarters since. 131 funds tracked by Wall St. Rank hold TAK as of Q3 2026.
- AssetMark Inc held 289,107 shares of Takeda Pharmaceutical worth $5.26M as of Q3 2026.
- AssetMark Inc sold 25,580 Takeda Pharmaceutical shares in Q3 2026, an estimated $453K.
- Takeda Pharmaceutical made up 0.01% of AssetMark Inc's portfolio in Q3 2026, its #731 holding.
- AssetMark Inc first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 29 quarters since.
- 131 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2026.
Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.